Actively Recruiting
Evaluation of Concordance Between Exhaled Air Test (eBAM-CoV) and RT-PCR to Detect SARS-CoV-2
Led by Centre Hospitalier Universitaire de Nīmes · Updated on 2025-03-24
250
Participants Needed
2
Research Sites
73 weeks
Total Duration
On this page
Sponsors
C
Centre Hospitalier Universitaire de Nīmes
Lead Sponsor
U
University of Nimes
Collaborating Sponsor
AI-Summary
What this Trial Is About
During the COVID-19 pandemic, testing primarily relied on the use of nasopharyngeal swabs to detect the SARS-CoV-2 virus, responsible for the disease. However, this technique has several limitations, including the variable quality of swabs, its invasive nature, and arbitrariness in the choice of the number of cycles. Furthermore, it does not allow for the detection of viral proteins. To overcome these limitations, researchers developed the eBAM-CoV test, patented for the detection of viral proteins in the exhaled air of COVID-19 patients. This portable device provides an immediate assessment of the "viral load" with both quantitative and qualitative results, showing promise for early virus detection. The researchers hypothesize that the eBAM-CoV test is likely to exhibit a satisfactory concordance with the reference RT-PCR test in the detection of COVID-19, especially among symptomatic patients or closed contacts.
CONDITIONS
Official Title
Evaluation of Concordance Between Exhaled Air Test (eBAM-CoV) and RT-PCR to Detect SARS-CoV-2
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult male or female patients 18 years of age or older
- Suspected of being infected with COVID-19 (symptomatic or contact case) and consulting for RT-PCR screening
You will not qualify if you...
- Unable to understand the procedures to use the device
- Currently participating in another interventional study
- Within an exclusion period determined by another study
- Under court protection or guardianship
- Patient or representative unable to provide informed information
- Pregnant, parturient, or breastfeeding patient
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Laboratoire Alphabio, Hôpital Européen Marseille
Marseille, France, 13003
Not Yet Recruiting
2
CHU de NIMES
Nîmes, France, 30029
Actively Recruiting
Research Team
V
Valérie COMPAN, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here